A Journey Through Migraine: Using Modern Evidence, Expert Insight, and Practice Simulation to Navigate Daily Challenges

Due to the unique educational design of this course, the content must be viewed and completed on the myCME platform.

Program Description

1 in 6 adults in the US suffers from migraines, yet despite its widespread prevalence and burden, migraines continue to be underdiagnosed and undertreated. Additionally, even with the well-documented drawbacks of many traditional acute and preventive migraine therapies, these agents are often prioritized, and novel agents sub optimally integrated into management.

To assist clinicians in the application of contemporary diagnostic and treatment approaches for their migraine patients, this activity features a roundtable discussion featuring two headache specialists – Drs. Jessica Ailani and Ryan Smith – and primary care provider, Dr. Charles Vega.

Note that the core activity is supplemented by an interactive patient simulation. This clinical tool was developed to assist clinicians in considering how best to implement migraine treatment into their own day-to-day practice.

Target Audience

The target audience for this activity includes primary healthcare physicians, headache specialists, general neurologists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with migraines.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Review published data and patient perspectives on persistent diagnostic barriers in migraine as well as practical assessment tools that may help mitigate their occurrence to characterize migraine more rapidly and effectively
  • Evaluate the differential benefits of phase 3 data with, and patient selection for recently approved therapies for the acute management of migraine to better customize treatment to individual patients
  • Discuss the changing paradigm of migraine preventive therapy, including increasingly blurred lines with acute therapy, in light of recently approved agents (CGRP mAbs, gepants for prevention) to determine how that may influence patient selection and long-term strategy
  • Develop customized and comprehensive acute and preventive treatment regimens based on a patient’s migraine classification, needs, and preferences
Course summary
Course opens: 
Course expires: 
   Ryan Smith DO, FAAN (Moderator)
   Assistant Professor of Neurology
   Idaho College of Osteopathic Medicine
   Clinical Instructor
   University of Washington
   Chair of Medicine Treasure Valley and Medical Director of Outpatient Neurology
   St Luke's Health System
   Boise, ID
   Jessica Ailani, MD, FAHS
   Director, Georgetown Headache Center
   Professor of Clinical Neurology
   Vice Co-Chair Strategic Planning Neurology
   Medstar Georgetown University Hospital
   Washington, DC 
   Charles Vega, MD
   Associate Dean and Clinical Professor of Family Medicine
   University of California, Irvine School of Medicine
   Orange, CA

This activity is jointly provided by Purdue University College of Pharmacy Office of Continuing Education and Professional Development (Purdue) and Efficient LLC.


Accreditation Statement

This enduring activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy Office of Continuing Education and Professional Development and Efficient LLC. Purdue University, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.


Designation Statement

Purdue University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/ equal opportunity institution.

Purdue will award a maximum of 1.00 contact hours (0.1 CEUs) to pharmacists who participate in this knowledge-based activity series. Universal Activity Number (UAN): 0018-9999-24-013-H01-P, 1.00 contact hour (0.10 CEU). Release Date: 05/10/2024 Expiration Date: 05/10/2025.


The American Association of Nurse Practitioners (NPs) accepts AMA PRA Category 1 Credit™ from providers accredited by the ACCME. Additionally, the American Academy of Physician Assistants (PAs) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from providers accredited by the ACCME. As a result, NPs and PAs will be included as a target audience.

A Certificate of Participation will be given upon completion of the live activity enabling participants to register their credit with the appropriate licensing boards or associations.

Conflicts of Interest Disclosure Policy

To ensure compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Purdue University requires that all individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest identified are thoroughly assessed by Purdue University to ensure fair balance, scientific rigor, and accepted patient care recommendations of the educational activity. 

All relevant conflicts of interest have been mitigated prior to the start of the activity.

None of the planners, reviewers, Efficient LLC staff, and Purdue University College of Pharmacy staff have relevant financial relationship(s) with ineligible companies to disclose unless listed below.

Faculty Disclosures

Dr Vega has no financial relationships to disclose.

Dr Ailani reports the following financial relationships:

  • Consulting fees: Allergan/Abbvie, Amgen, Biohaven Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline, Impel Pharmaceuticals, Inc., Ipsen Biopharmaceuticals, Inc., Lilly, Lundbeck, Merz, Miravo, Neurolief Inc., Pfizer Inc., Satsuma Pharmaceuticals Inc., Teva Pharmaceuticals, Theranica
  • Contracted research: Allergan/Abbvie, Biohaven Pharmaceuticals Inc., Lilly, Ipsen Biopharmaceuticals, Satsuma Pharmaceuticals Inc.
  • Fees for Non-CME/CE Services: Aeon, Gore

Dr Smith reports the following financial relationships:

  • Consulting fees: AbbVie
  • Speaker Bureau: AbbVie

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support

Supported by an educational grant from Pfizer.


Please login or register to take this course.
Due to the unique educational design of this course, the content must be viewed and completed on the myCME platform.